80%Confidence
0Views
FDASource
2026-04-21Date
Summary
Fresenius Kabi has a sterility assurance recall for a sodium chloride injection product, indicating potential manufacturing process failures. This could lead to supply disruptions and increased regulatory scrutiny for its injectables portfolio.
Actionable: Assess the impact on Fresenius Kabi's revenue and consider competitors like Baxter or B. Braun as potential beneficiaries of market share shifts.
AI Confidence: 80%
Data Points
firmFresenius Kabi USA, LLC
classificationClass II
statusOngoing
distributionUS Nationwide , Alaska, and Puerto Rico.
product0.9% Sodium Chloride Injection, USP, (2,250 mg per 250 mL) (9 mg per mL) 250 mL in a 250 mL freeflex bag, Rx only, Fresenius Kabi USA, LLC ("Fresenius
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now